Clinical Trial Update: A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). [Phase 3]

View source ↗

Summary

Phase 3 COPD trial evaluating inhaled budesonide/glycopyrronium/formoterol fumarate MDI (BGF), budesonide/formoterol fumarate MDI (BFF), and placebo MDI; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BFF MDI (budesonide/formoterol fumarate)
• BGF MDI (budesonide/formoterol)
• Placebo MDI

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED